Other Nomacopan-based Molecules

Akari is developing engineered versions of nomacopan that decrease frequency of administration, improve potency, and allow for specific tissue targeting, as well as new proteins targeting LBT4 alone, and bioamine inhibitors (for example, anti-histamines). In general, these inhibitors act as ligand binding compounds, which may provide additional benefit versus other modes of inhibition.